Supreme Court to Hear Generic Drug Appeal



Nov. 8 (Bloomberg) — The U.S. Supreme Court will hear the oral arguments in a case between Novo Nordisk A/S, the manufacturer of diabetes drug Prandin, and generic drug maker Caraco Pharmaceutical Laboratories, Ltd. The legal dispute, over the manufacture of a generic version of the drug, centers on interpretation of the Hatch-Waxman Act and could change how brand-name drug makers use patent law. Tony Dutra, legal editor of BNA’s Patent, Trademark & Copyright Journal, talks with Bloomberg Law’s Josh Block about the case which will be argued before the Court on Dec. 5.